Innovative Medicine

Innovative Medicine

March 7, 2013

Janssen Submits European Marketing Authorisation Application for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes

Innovative Medicine

March 5, 2013

FDA Issues Complete Response Letter for XARELTO® (rivaroxaban) for the Reduction of Cardiovascular Events in Patients with Acute Coronary Syndrome

Innovative Medicine

February 22, 2013

Janssen Files First Regulatory Application for Simeprevir (TMC435) for the Treatment of Genotype 1 Hepatitis C Patients in Japan

Innovative Medicine

February 13, 2013

Janssen Healthcare Innovation launches inaugural Innovation Challenge Prize for Dementia in collaboration with the NHS

Innovative Medicine

February 12, 2013

Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration

Investigational oncology agent for B-cell malignancies jointly being developed by Janssen and Pharmacyclics

Innovative Medicine

February 12, 2013

Follow-up Data Show ZYTIGA® Plus Prednisone Continues to Delay Progression of Metastatic Castration-Resistant Prostate Cancer in Patients without Prior Chemotherapy

Innovative Medicine

February 5, 2013

XARELTO® to be Studied with Factor Xa Inhibitor Antidote

Janssen and Bayer Announce Clinical Collaboration Agreement with Portola

Innovative Medicine

January 11, 2013

ZYTIGA® Approved In The EU For Use In The Treatment Of Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy

Innovative Medicine

January 10, 2013

FDA Advisory Committee Recommends Approval of Canagliflozin for Treatment of Adults with Type 2 Diabetes